Progression-free survival - PDFSEARCH.IO - Document Search Engine

Progression-free survival
Results: 42

#	Item
21	Carboplatin Injection Progression-Free Survival (PFS) NCIC Add to Reading List Source URL: www.sagentpharma.com Language: English - Date: 2013-11-01 11:16:00 Carboplatin Cisplatin Ototoxicity Creatinine National Cancer Institute Thrombocytopenia Gemcitabine Triplatin tetranitrate Chemistry Alkylating antineoplastic agents Ammine complexes
22	Errata to the FDA Briefing Package Add to Reading List Source URL: www.fda.gov Language: English Logrank test Vandetanib Proportional hazards models Progression-free survival Hazard ratio Hazard AstraZeneca Statistics Survival analysis Chemistry
23	Assessing Bias in the Determination of Disease Progression in Non-Hematologic Malignancies Rajeshwari Sridhara, Ph.D. Division Director Add to Reading List Source URL: www.fda.gov Language: English Internet Relay Chat IRC Carcinoid Medicine Oncology Progression-free survival
24	U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may Add to Reading List Source URL: www.fda.gov Language: English Medical statistics Health Epidemiology Medical research Surrogate endpoint End point of clinical trials Progression-free survival Ovarian cancer FDA Fast Track Development Program Medicine Clinical trials Medical terms
25	FDA Briefing Document Oncologic Drugs Advisory Committee Meeting July 24, 2012 Evaluation of Radiologic Review of Progression-free Survival in Non-hematologic Malignancies Add to Reading List Source URL: www.fda.gov Language: English Clinical research Design of experiments Pharmacology Medicine Food and Drug Administration Progression-free survival Clinical trial Randomized controlled trial Audit Epidemiology Research Pharmaceutical sciences
26	Use of blinded independent central review of PFS Lori E. Dodd, PhD Biostatistics Research Branch National Institute of Allergy and Infectious Diseases Add to Reading List Source URL: www.fda.gov Language: English Progression-free survival Epidemiology End point of clinical trials Medicine Hazard ratio Health Medical statistics Statistics Clinical trials
27	NDA[removed]S013 Sutent (sunitinib malate) ODAC Briefing Document FDA Briefing Document Add to Reading List Source URL: www.fda.gov Language: English Indoles Pfizer Pyrroles Sunitinib Renal cell carcinoma Neuroendocrine tumor Progression-free survival Response Evaluation Criteria in Solid Tumors End point of clinical trials Medicine Medical statistics Organofluorides
28	U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may Add to Reading List Source URL: www.fda.gov Language: English Progression-free survival Medicine Hazard ratio Health Clinical endpoint Medical statistics Statistics End point of clinical trials
29	Endpoints in Ovarian Cancer Clinical Trials Add to Reading List Source URL: www.fda.gov Language: English
30	FDA Approvals in Multiple Myelomar Add to Reading List Source URL: www.fda.gov Language: English Clinical trials Food and Drug Administration Medical terms Medical statistics Medical research FDA Fast Track Development Program Surrogate endpoint End point of clinical trials Progression-free survival Medicine Health Clinical research